Tramadol is a synthetic opioid and SNRI prescribed for moderate pain. It carries unique risks due to its dual mechanism — opioid agonism plus serotonin/norepinephrine reuptake inhibition — making it dangerous in combination with serotonergic drugs. It also lowers the seizure threshold significantly.
What the Community Wants You to Know
Tramadol is the only commonly prescribed opioid that carries significant seizure risk. If you take tramadol and experience muscle twitching, jaw clenching, or involuntary limb movements, these may be warning signs of impending seizure activity. Stop taking tramadol and consult a physician. This risk exists even at prescribed doses in some individuals.
'Tramadol is a safe opioid' — this is the most dangerous misconception about tramadol. While it is less likely to cause fatal respiratory depression than morphine or oxycodone, it introduces risks that other opioids do not: seizures, serotonin syndrome, and a withdrawal syndrome that is worse than what you would expect from an opioid of its potency. Different does not mean safer.
If tramadol does absolutely nothing for your pain, you are very likely a CYP2D6 poor metabolizer. Your liver cannot convert tramadol into its active opioid metabolite (O-desmethyltramadol). You are still getting the SNRI effects, just not the opioid analgesia. Tell your doctor — a different analgesic will work better for you. Conversely, if tramadol hits you unusually hard, get pharmacogenomic testing done.
Safety at a Glance
High Risk- Seizure Prevention
- Additional seizure risk reduction measures:
- Toxicity: Seizure Risk Seizures are the defining toxicological concern with tramadol and the feature that most sharply distingu...
- Dangerous with: Alcohol, Alprazolam, Diazepam, Fenfluramine, Cocaine (+4 more)
- Overdose risk: Presentation Tramadol overdose presents differently from typical opioid overdoses, and this diffe...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
Oral
Duration
Oral
Total: 4 hrs – 7 hrsHow It Feels
The Tramadol Experience
Tramadol is the drug that defies expectations in every direction. If you approach it expecting a proper opioid experience, you will be underwhelmed. If you dismiss it as harmless because it seems weak, you may end up in an ambulance with a seizure. It occupies a strange pharmacological middle ground — part opioid, part antidepressant, fully its own thing — and the experience reflects that duality at every turn.
Onset (30-60 minutes)
You swallow the capsule or tablet and wait. Unlike the dramatic onset of some opioids, tramadol announces itself quietly. Around 30-45 minutes in, there is a subtle shift — a gentle lifting of mood that feels less like a drug kicking in and more like receiving good news. The world does not change, but your relationship to it softens slightly. Your shoulders drop. The low-grade anxiety that you carry around like a backpack loosens its straps.
The SNRI component makes itself felt first in most people. There is a mild but noticeable increase in motivation and energy — you might find yourself wanting to tidy your desk, reply to emails, or call a friend. This stimulating quality is what catches opioid-experienced users off guard. This is not the drowsy, nodding warmth of hydrocodone. This is closer to what a first dose of Effexor feels like if Effexor worked in 45 minutes instead of 4 weeks.
Peak (1.5-3 hours)
As the M1 metabolite builds in your bloodstream, the opioid component becomes more apparent. A gentle warmth spreads through your body — not the overwhelming full-body embrace of stronger opioids, but a quiet, pleasant coziness. Pain, if present, recedes from the foreground to background noise. There is a sense of being okay with things, of not needing the world to be different from how it is.
Conversation flows more easily. You are slightly more talkative, slightly more engaged, slightly more present. Someone unfamiliar with pharmacology might not identify this as an opioid effect at all — it feels more like a good mood than a high. Many people who take tramadol as prescribed for chronic pain describe this as its greatest virtue: it takes the edge off pain without taking the edge off your personality.
At higher doses (200-300mg for non-tolerant users), the opioid character becomes more pronounced. The warmth deepens, drowsiness appears, and the experience starts to resemble a low-dose codeine experience. But even at these doses, there is a floor — tramadol simply cannot produce the intensity of euphoria that full mu-agonists deliver, which is both its therapeutic advantage and the source of recreational disappointment.
The nausea, unfortunately, is a constant companion for many users. Tramadol-induced nausea is persistent and often worse than what other opioids produce, particularly in the first days of use. It can be partially managed with ginger or ondansetron but is the reason many patients ask to switch medications.
Offset and Aftermath
The comedown from tramadol is gentle — the mood elevation fades gradually over 2-4 hours, and there is rarely a dramatic crash. Some users report feeling slightly flat or mildly depressed in the hours following, likely due to the SNRI rebound, but this is subtle compared to the comedowns of most recreational substances.
What makes tramadol treacherous is not the single experience but the pattern it establishes. The mild mood elevation, the increased sociability, the sense of quiet competence — these are effects that integrate seamlessly into daily life. Tramadol does not make you obviously impaired. It makes you feel like a slightly better version of yourself. And that is exactly the mechanism by which daily use creeps in, tolerance builds, doses escalate, and the uniquely hellish tramadol withdrawal — which combines opioid sickness with SNRI brain zaps — eventually arrives.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Constipation— A slowing or cessation of bowel movements resulting in difficulty passing stool, commonly caused by ...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Pupil constriction— A visible narrowing of the pupil diameter (miosis) that reduces the size of the dark center of the e...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(4)
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
Community Insights
Harm Reduction(1)
Tramadol is the only commonly prescribed opioid that carries significant seizure risk. If you take tramadol and experience muscle twitching, jaw clenching, or involuntary limb movements, these may be warning signs of impending seizure activity. Stop taking tramadol and consult a physician. This risk exists even at prescribed doses in some individuals.
Based on 1 community posts · 0 combined upvotes
Common Misconceptions(1)
'Tramadol is a safe opioid' — this is the most dangerous misconception about tramadol. While it is less likely to cause fatal respiratory depression than morphine or oxycodone, it introduces risks that other opioids do not: seizures, serotonin syndrome, and a withdrawal syndrome that is worse than what you would expect from an opioid of its potency. Different does not mean safer.
Based on 1 community posts · 0 combined upvotes
Community Wisdom(1)
If tramadol does absolutely nothing for your pain, you are very likely a CYP2D6 poor metabolizer. Your liver cannot convert tramadol into its active opioid metabolite (O-desmethyltramadol). You are still getting the SNRI effects, just not the opioid analgesia. Tell your doctor — a different analgesic will work better for you. Conversely, if tramadol hits you unusually hard, get pharmacogenomic testing done.
Based on 1 community posts · 0 combined upvotes
Pharmacology
Mechanism of Action
Tramadol exerts its effects through two distinct and complementary mechanisms, making it pharmacologically unique among opioid analgesics.
Mu-Opioid Receptor Agonism
Tramadol itself has only weak affinity for the mu-opioid receptor — roughly 6,000 times weaker than morphine. The real opioid activity comes from its primary metabolite,O-desmethyltramadol (M1), which is produced by hepatic CYP2D6-mediated O-demethylation. M1 has approximately 200 times greater affinity for the mu-opioid receptor than the parent compound and is responsible for the majority of tramadol's analgesic and euphoric effects. This metabolic dependency is the reason tramadol's effects vary so dramatically between individuals based on their CYP2D6 phenotype.
Serotonin-Norepinephrine Reuptake Inhibition
The (+)-enantiomer of tramadol inhibits serotonin reuptake, while the (-)-enantiomer inhibitsnorepinephrine reuptake. This dual monoamine reuptake inhibition is pharmacologically similar to antidepressant medications like venlafaxine (Effexor) and duloxetine (Cymbalta). The SNRI activity contributes to tramadol's analgesic effects via descending pain inhibitory pathways in the spinal cord, and also produces the mood-elevating and mildly stimulating properties that distinguish tramadol from pure opioid agonists.
CYP2D6 Polymorphism
CYP2D6 genetic variation profoundly affects tramadol's clinical profile:
- Ultra-rapid metabolizers (~5-10% of Caucasians, higher in some Middle Eastern and African populations): produce excessive M1, resulting in enhanced opioid effects and increased risk of respiratory depression and overdose even at standard doses
- Extensive metabolizers (majority): normal tramadol response and analgesic efficacy
- Intermediate metabolizers (~10-15%): reduced analgesic efficacy, may require higher doses
- Poor metabolizers (~5-10% of Caucasians): produce minimal M1, resulting in poor analgesia but retained SNRI effects — these patients essentially receive an antidepressant with negligible opioid activity
Pharmacokinetics
- Oral bioavailability: approximately 75% (single dose), increasing to ~100% with repeated dosing
- Time to peak plasma concentration: 1.5-2 hours (immediate release)
- Elimination half-life: 5-7 hours (tramadol), 7-9 hours (M1 metabolite)
- Protein binding: approximately 20%
- Metabolism: primarily hepatic via CYP2D6 (O-demethylation to M1) and CYP3A4 (N-demethylation)
- Elimination: 90% renal, primarily as metabolites
Detection Methods
Tramadol is not detected by standard opiate immunoassay drug screens. Its chemical structure is sufficiently different from morphine, codeine, and other phenanthrene opioids that it does not cross-react with the antibodies used in standard 5-panel, 10-panel, or 12-panel drug tests. A standard urine drug screen that tests positive for "opiates" will not detect tramadol, and a negative opiate screen does not rule out tramadol use.
Detection requires a specific tramadol and O-desmethyltramadol immunoassay or confirmatory testing viagas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). Expanded drug panels used by some employers, pain management clinics, and forensic laboratories may include a tramadol-specific component.
Detection windows:
- Urine: tramadol and metabolites are detectable for2-4 days after last use in most individuals; chronic use may extend the window to 7 days
- Blood/serum: detectable for12-24 hours after a single therapeutic dose
- Hair: up to90 days (1-3 months) depending on hair growth rate and sampling method
- Saliva: approximately24-48 hours after last use
Forensic toxicology laboratories routinely screen for tramadol in post-mortem cases, and its presence alongside other CNS depressants is a significant finding in death investigations.
Interactions
| Substance | Status | Note |
|---|---|---|
| Alcohol | Dangerous | Both are CNS depressants. Tramadol's opioid effects combined with alcohol's depressant effects can cause fatal respiratory depression. Tramadol also lowers the seizure threshold, and alcohol withdrawal can trigger seizures. |
| Alprazolam | Dangerous | Opioid + benzodiazepine combinations are a leading cause of overdose death. Both cause respiratory depression and the effects are synergistic, not just additive. |
| Diazepam | Dangerous | Opioid + benzodiazepine combinations are a leading cause of overdose death. Both cause respiratory depression and the effects are synergistic, not just additive. |
| Fenfluramine | Dangerous | Additive serotonergic activity plus seizure threshold lowering. |
| GHB | Dangerous | Both are CNS depressants. The combination carries high risk of fatal respiratory depression and loss of consciousness. |
| MAOIs | Dangerous | Potentially fatal combination. MAOIs prevent the breakdown of serotonin while tramadol inhibits its reuptake, leading to rapid serotonin accumulation. Multiple deaths have been reported from this combination. |
| MDMA | Dangerous | Both tramadol and MDMA have significant serotonergic activity. This combination carries a high risk of serotonin syndrome, which can be fatal. Tramadol also lowers the seizure threshold, and MDMA-induced hyperthermia further increases seizure risk. |
| SSRIs | Dangerous | Tramadol is an SNRI in addition to being an opioid. Combined with SSRIs, the serotonergic effects stack, creating a high risk of serotonin syndrome. Tramadol also lowers the seizure threshold, which SSRIs can further reduce. |
| Cocaine | Unsafe | Cocaine's stimulant effects may mask tramadol's sedation, leading to inadvertent overdose. Additionally, both affect serotonin — tramadol as an SNRI and cocaine as a triple reuptake inhibitor — creating serotonin syndrome risk. |
| Ketamine | Caution | Both are CNS depressants with some serotonergic activity. Increased risk of sedation, respiratory depression, and potential serotonin-related complications. |
| Cannabis | Low Risk & Synergy | Cannabis may potentiate tramadol's analgesic and sedative effects. Generally considered low risk, though increased sedation should be expected. |
History
Development
Tramadol was synthesized in 1962 by the German pharmaceutical companyGrunenthal GmbH — the same company responsible for thalidomide, a fact that haunts the company's reputation to this day. The compound was developed as part of a deliberate effort to create an effective analgesic with lower abuse potential than traditional opioids, a goal that seemed prescient given the escalating opioid crisis decades later but proved overly optimistic.
Early Commercial History
Tramadol was first marketed in 1977 in Germany under the brand nameTramal. Throughout the 1980s and 1990s, it expanded across European markets, consistently promoted as an opioid with minimal abuse liability. This marketing position was supported by early clinical data showing lower rates of euphoria and reinforcing effects compared to codeine and morphine.
US Approval and Scheduling
The FDA approved tramadol for use in the United States in 1995 as an unscheduled prescription medication — a remarkable distinction given that it was being marketed as an opioid analgesic. For nearly two decades, tramadol existed in a regulatory anomaly: an opioid that was not a controlled substance. During this period, prescriptions surged, particularly as concerns about stronger opioids grew and physicians sought "safer" alternatives.
By the early 2010s, evidence of tramadol misuse, diversion, and dependence had accumulated sufficiently that the DEA placed tramadol into Schedule IV of the Controlled Substances Act inAugust 2014. By this point, tramadol had already become one of the most widely prescribed analgesics in the world, with particular prevalence in regions of the Middle East and West Africa where it became a major drug of abuse.
Harm Reduction
Seizure Prevention
The single most critical harm reduction message for tramadol is: never exceed 400mg per day. Tramadol lowers the seizure threshold dose-dependently, and exceeding this ceiling dramatically increases the risk of generalized tonic-clonic seizures. This is not a soft guideline — it is a hard pharmacological ceiling that should never be crossed.
Additional seizure risk reduction measures:
- Never combine tramadol with other substances that lower seizure thresholds — this includes bupropion (Wellbutrin), antipsychotics, stimulants, and fluoroquinolone antibiotics
- Do not take tramadol if you have a history of seizure disorders or epilepsy
- Avoid abrupt discontinuation after chronic use — seizures can occur during withdrawal as well as during use
- Do not increase doses rapidly — gradual titration reduces seizure risk
Serotonin Syndrome Prevention
This is where tramadol becomes uniquely dangerous among opioids. Do not combine tramadol with:
- SSRIs (fluoxetine, sertraline, citalopram, escitalopram, paroxetam, fluvoxamine)
- SNRIs (venlafaxine, duloxetine, desvenlafaxine)
- MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline) — this combination isabsolutely contraindicated and can be rapidly fatal
- St. John's Wort — a commonly overlooked serotonergic supplement
- Triptans (sumatriptan, rizatriptan) used for migraines
- Lithium
- MDMA — the combination carries extremely high serotonin syndrome risk
Serotonin syndrome symptoms include high fever, muscle rigidity, clonus (rhythmic muscle contractions), agitation, rapid heart rate, and confusion. It is a medical emergency requiring immediate treatment.
General Opioid Safety
- Do not combine with alcohol, benzodiazepines, or other CNS depressants — despite tramadol's weaker respiratory depression profile, combinations still carry significant risk
- Test any non-prescription tramadol with fentanyl test strips — counterfeit tramadol pills containing fentanyl have been documented
- Start with the lowest effective dose and increase gradually
- Do not crush or break extended-release formulations — this releases the full dose at once, increasing seizure and overdose risk
Tapering and Discontinuation
Tramadol withdrawal is uniquely unpleasant because it combines opioid withdrawal symptoms (restless legs, diarrhea, sweating, muscle aches) with SNRI discontinuation syndrome (brain zaps, emotional lability, dizziness, electric shock sensations). If you have been taking tramadol daily for more than 2 weeks:
- Taper gradually — reduce by no more than 10-25% of the dose every 3-5 days
- Do not stop abruptly — abrupt cessation increases the risk of seizures and produces severe withdrawal
- Consult a physician if possible, especially if you have been on high doses or prolonged use
CYP2D6 Awareness
If tramadol provides unexpectedly strong effects or virtually no pain relief, you may have an atypical CYP2D6 phenotype. Pharmacogenomic testing is increasingly available and can identify ultra-rapid or poor metabolizers. This is particularly important for patient safety — ultra-rapid metabolizers have died from standard tramadol doses.
Toxicity & Safety
Seizure Risk
Seizures are the defining toxicological concern with tramadol and the feature that most sharply distinguishes it from other opioids. Tramadol lowers the seizure threshold in a dose-dependent manner through mechanisms related to both its opioid and monoamine reuptake inhibition activities. Seizure risk increases significantly:
- At doses above 400mg per day (the recommended ceiling)
- In patients with a history of seizure disorders
- When combined with other substances that lower seizure thresholds — including SSRIs, SNRIs, tricyclic antidepressants, bupropion, antipsychotics, and other opioids
- During abrupt withdrawal after chronic use
- In the context of rapid dose escalation
Seizures are typically generalized tonic-clonic (grand mal) and can occur even at therapeutic doses in susceptible individuals. Epidemiological data suggest a seizure incidence of approximately 8-35 per 100,000 patient-years at recommended doses, increasing substantially with supratherapeutic dosing.
Serotonin Syndrome
Tramadol's SNRI activity creates a risk of serotonin syndrome when combined with other serotonergic agents. This is a potentially life-threatening condition characterized by:
- Neuromuscular excitability (clonus, hyperreflexia, myoclonus, tremor)
- Autonomic dysfunction (hyperthermia, tachycardia, diaphoresis, diarrhea)
- Altered mental status (agitation, confusion, delirium)
The highest-risk combinations are tramadol with MAOIs (absolutely contraindicated — must allow 14-day washout),SSRIs,SNRIs,triptans,St. John's Wort, andlithium.
Respiratory Depression
Respiratory depression occurs at a lower rate than with typical mu-agonist opioids due to tramadol's weak direct opioid activity. However, it remains clinically significant in:
- CYP2D6 ultra-rapid metabolizers (excessive M1 production)
- Overdose situations
- Combinations with other CNS depressants (benzodiazepines, alcohol, other opioids)
Hepatotoxicity
Chronic use at high doses has been associated with elevated liver enzymes and, in rare cases, clinically significant hepatotoxicity. Patients with pre-existing liver disease are at increased risk and may have altered metabolism of tramadol, leading to unpredictable effects.
Addiction Potential
Tramadol is moderately addictive, with an abuse potential that was systematically underestimated for decades. Physical dependence develops with regular use over 2-4 weeks, and the withdrawal syndrome is uniquely unpleasant because it combines classical opioid withdrawal symptoms (restless legs, diarrhea, muscle aches, sweating, insomnia) with SNRI discontinuation syndrome (brain zaps, emotional lability, dizziness, electric shock sensations, severe mood swings). This dual withdrawal makes tramadol discontinuation subjectively worse than withdrawal from equi-analgesic doses of pure opioid agonists, according to many patients who have experienced both.
Overdose Information
Presentation
Tramadol overdose presents differently from typical opioid overdoses, and this difference can be life-threatening if emergency responders treat it as a straightforward opioid OD.
Seizures are the primary and most dangerous manifestation of tramadol overdose. Generalized tonic-clonic seizures can occur as the first sign of overdose, sometimes before significant respiratory depression develops. This is the opposite of what happens with morphine or heroin overdoses, where respiratory depression is the leading threat.
Additional overdose symptoms include:
- Serotonin syndrome (hyperthermia, clonus, agitation, diaphoresis)
- Respiratory depression (present but typically less severe than with full mu-agonists)
- Altered mental status progressing to coma
- Tachycardia or cardiovascular instability
- Nausea and vomiting with aspiration risk
Emergency Response
- Call 911 immediately — tramadol overdose can deteriorate rapidly due to seizures
- Naloxone (Narcan) is partially effective — it reverses only the opioid component of tramadol toxicity. Naloxone will NOT prevent or treat tramadol-induced seizures and will not reverse serotonin syndrome. Administer naloxone if respiratory depression is present, but do not rely on it as a complete antidote
- Benzodiazepines are the first-line treatment for tramadol-induced seizures in the emergency setting
- Place the person in the recovery position if unconscious
- Monitor for hyperthermia — active cooling may be necessary if serotonin syndrome is present
- Do not induce vomiting — seizure risk makes this dangerous
Lethal Dose
Fatal tramadol overdoses have been reported at doses as low as 2-5 grams, though the lethal dose varies enormously based on CYP2D6 phenotype, co-ingestants, and tolerance. Ultra-rapid metabolizers are at significantly greater risk. Deaths from tramadol alone, while less common than deaths from stronger opioids, are well-documented and are almost always associated with seizures or serotonin syndrome rather than isolated respiratory depression.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both are CNS depressants. Tramadol's opioid effects combined with alcohol's depressant effects can cause fatal respiratory depression. Tramadol also lowers the seizure threshold, and alcohol withdrawal can trigger seizures.
Opioid + benzodiazepine combinations are a leading cause of overdose death. Both cause respiratory depression and the effects are synergistic, not just additive.
Cocaine's stimulant effects may mask tramadol's sedation, leading to inadvertent overdose. Additionally, both affect serotonin — tramadol as an SNRI and cocaine as a triple reuptake inhibitor — creating serotonin syndrome risk.
Opioid + benzodiazepine combinations are a leading cause of overdose death. Both cause respiratory depression and the effects are synergistic, not just additive.
Additive serotonergic activity plus seizure threshold lowering.
Both are CNS depressants. The combination carries high risk of fatal respiratory depression and loss of consciousness.
Potentially fatal combination. MAOIs prevent the breakdown of serotonin while tramadol inhibits its reuptake, leading to rapid serotonin accumulation. Multiple deaths have been reported from this combination.
Both tramadol and MDMA have significant serotonergic activity. This combination carries a high risk of serotonin syndrome, which can be fatal. Tramadol also lowers the seizure threshold, and MDMA-induced hyperthermia further increases seizure risk.
Tramadol is an SNRI in addition to being an opioid. Combined with SSRIs, the serotonergic effects stack, creating a high risk of serotonin syndrome. Tramadol also lowers the seizure threshold, which SSRIs can further reduce.
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Tramadol is classified as a Schedule IV controlled substance in the United States as of August 2014, following a DEA final rule that recognized its potential for abuse and dependence after nearly two decades of unscheduled availability. Prior to scheduling, tramadol was one of the most widely prescribed uncontrolled opioids in the country.
Internationally, tramadol's legal status varies considerably:
- European Union: prescription-only medication in all member states; not uniformly scheduled as a controlled substance at the EU level, but individual countries may apply additional controls
- United Kingdom: Class C controlled substance and Schedule 3 under the Misuse of Drugs Regulations, prescription-only
- Germany: prescription-only, available as Tramal and generics — one of the most commonly prescribed opioids in German pain medicine
- Australia: Schedule 4 (prescription-only medicine)
- Canada: prescription medication, not specifically scheduled under the Controlled Drugs and Substances Act
- India: prescription medication but widely available informally; significant recreational use documented
- Egypt and West Africa: tramadol abuse has reached epidemic proportions in several countries, particularly Egypt, Nigeria, Cameroon, and Niger, leading to emergency scheduling and import restrictions. The WHO Expert Committee on Drug Dependence has repeatedly reviewed tramadol's scheduling status at the international level
- China: controlled substance since 2007
Tramadol remains available by prescription in most countries worldwide and continues to be one of the most prescribed opioid analgesics globally, with an estimated 44 million prescriptions filled annually in the United States alone.
Experience Reports (2)
Tips (5)
Do NOT combine tramadol with SSRIs, SNRIs, or MAOIs. Tramadol is an SNRI itself, and stacking serotonergic drugs creates a very real risk of serotonin syndrome — a potentially fatal condition. If you are prescribed an antidepressant and your doctor prescribes tramadol, make sure they know about the interaction. Many prescribers are not aware of tramadol's serotonergic activity.
Never exceed 400mg of tramadol in a 24-hour period. Tramadol lowers the seizure threshold dose-dependently, and doses above this ceiling dramatically increase the risk of grand mal seizures. This is not a guideline — it is a hard pharmacological limit. Seizures can occur without warning and are the leading cause of serious tramadol-related emergencies.
If your tramadol was not dispensed from a licensed pharmacy, test it with fentanyl test strips before use. Counterfeit tramadol tablets containing fentanyl have been documented in illicit supply chains. A pill that looks identical to pharmaceutical tramadol can contain a lethal dose of fentanyl. Two dollars for a test strip versus your life.
If you have been taking tramadol daily for more than 2 weeks, do not stop abruptly. Tramadol withdrawal combines opioid withdrawal (restless legs, sweating, diarrhea) with SNRI discontinuation (brain zaps, mood swings, electric shock sensations). Taper by reducing 10-25% every 3-5 days. The dual withdrawal mechanism makes cold turkey from tramadol uniquely miserable.
Tramadol's opioid effects depend almost entirely on CYP2D6 metabolism. If tramadol gives you zero pain relief, you may be a CYP2D6 poor metabolizer — your body cannot convert it to the active M1 metabolite. If tramadol hits you unusually hard, you may be an ultra-rapid metabolizer, which carries serious overdose risk. Pharmacogenomic testing is available and can identify your phenotype.
See Also
References (4)
- Tramadol — PubChem CID 33741
Chemical data, structure, physical properties, and biological activity information.
database - Tramadol — Wikipedia
Comprehensive overview of tramadol including pharmacology, history, and clinical use.
encyclopedia - Tramadol — TripSit Factsheets
Harm reduction information including dosage, interactions, and subjective effects.
harm_reduction - Tramadol: a review of its use in perioperative pain — Grond & Sablotzki, 2004 — Grond S, Sablotzki A Drugs (2004)
Comprehensive clinical review of tramadol pharmacology, efficacy, and safety profile.
paper